

**HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)  
SOMATROGON FOR TREATING GROWTH DISTURBANCE IN CHILDREN AND YOUNG PEOPLE  
AGED 3 YEARS AND OVER (NICE TA 863)**

**RED - RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST ONLY.  
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.**

<b>Name: generic (trade)</b>	<b>What it is</b>	<b>Indication</b>	<b>Date decision last revised</b>	<b>Decision status</b>	<b>NICE / SMC Guidance</b>
Somatrogon (Ngenla®)	Recombinant human growth hormone	Licensed for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.	March 2023	Interim*	NICE TA 863-recommended SMC – accepted for use

**HWE APC recommendation:**

Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance in children and young people aged 3 years and over in line with the recommendations in NICE TA863.

Somatrogon treatment should be reviewed in line with discontinuation criteria already agreed across HWE ICB for somatropin treatment:

- Poor response: growth velocity in the first 3 years of treatment <50% above baseline value for year 1, 2, 3 of treatment.
- Growth velocity is less than <2cm total growth in 1 year
- Final height is attained. Confirmation of final height: bone age is >14yrs (girls) or >16yrs (boys)
- Insurmountable problems with adherence

National tariff excluded.

If somatrogon is considered one of a number of suitable treatments (including any preparation of somatropin), the least expensive (taking into account administration costs, dosage, price per dose and commercial arrangements) should be chosen.

**RED STATUS\*:**

- **NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.**
- **RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALISTS**

*\* Prescribing RAG recommendation to be reviewed at a future HWE APC meeting following consultations with local specialists and tertiary centres*

**NICE TA 863 recommendations:**

- Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over.
- If people with the condition and their clinicians consider somatrogon to be 1 of a range of suitable treatments (including any preparation of somatropin) discuss the advantages and disadvantages of the available treatments. After that discussion, if more than 1 treatment is suitable, choose the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.